Cara Therapeutics Inc., of Shelton, Conn., said it earned a $500,000 milestone payment from Maruishi Pharmaceutical Co. Ltd., of Osaka, Japan, for the completion of its phase I trial of the I.V. formulation of Cara's kappa opioid agonist, CR845, in Japan.